Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer
BEVERLY, MA – January 24, 2013– Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has received results from in vivo studies conducted at Beth Israel Deaconess Medical Center (“BIDMC”). Cellceutix had earlier reported that they entered into an agreement with BIDMC, a teaching hospital of Harvard Medical School, on an innovative research project with Kevetrin™, the Company’s flagship anti-cancer drug. BIDMC wishes to exploit the nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.
Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”
Per protocol, Cellceutix has formally notified BIDMC that it has a strong interest in further collaborative efforts to develop combination treatments with Kevetrin and multikinase VEGF receptor antagonists, particularly VEGFR2 inhibitors. Cellceutix has provided the requested information that will be used to investigate a Specialized Programs of Research Excellence (SPORE) grant for a phase 2 clinical study.
Renal cell carcinoma is the most common type of kidney cancer in adults. BIDMC is the lead recipient of the prestigious National Cancer Institute-funded kidney cancer SPORE grant.
In 1992, the National Cancer Institute (NCI) established the Specialized Programs of Research Excellence (SPOREs), specialized cancer center grants to promote and speed up the exchange between interdisciplinary research in the laboratory to the treatment of patients in the clinical care setting.
SPORE programs allow laboratory and clinical scientists to work collaboratively to plan, design, and implement research programs with the greatest potential to impact cancer prevention, detection, diagnosis and treatment.
And note they will be moving into to grant funded Phase II clinical trials at Beth Israel. What does that suggest about the Phase I results that are going on at Dana Farber? While this is fantastic news, the big move will come when we see safety and efficacy in the current Phase I trials IMO.
Phase I is going well so far. Cohort 2 cycle 1 will be completed this week, and we should get a PR this weekend. Since Sunitinib is an approved drug, the Kevetrin/Sunitinib can start Phase II when the MTD of Kevetrin is established in Phase I. Looks like funding will not be a problem thanks to the SPORE grant. My guess is Phase II will start in late 2013 / early 2014.
Now that's impressive on renal cell line 786! I guess what's more impressive is that we're getting fresh data like this out of some of the best Cancer centers in the United States. And they are showing a continued interest in Kevetrin and CTIX. Great stuff! Only wish I owned more shares.